Savient Pharmaceuticals, Inc. (SVNT)
-NasdaqGM 0.56 
0.01(1.77%) May 24, 3:59PM EDT
| Prev Close: | 0.57 |
|---|
| Open: | 0.59 |
|---|
| Bid: | N/A |
|---|
| Ask: | 1.30 x 1900 |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | 2.36 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.54 - 0.59 |
|---|
| 52wk Range: | 0.48 - 2.95 |
|---|
| Volume: | 624,748 |
|---|
| Avg Vol (3m): | 436,853 |
|---|
| Market Cap: | 41.36M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.53 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SAVIENT PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- SVNT July Options Begin Tradingat TheStreet(Mon, May 20)
- 3 Pharmaceutical Stock Earnings Snapshotsat Wall St. Cheat Sheet(Sun, May 19)
- Savient downgraded to Market Perform from Outperform at William Blairtheflyonthewall.com(Fri, May 17)
- Savient Pharmaceuticals Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, May 15)
- Savient Pharmaceuticals Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 15)
- SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aEDGAR Online(Wed, May 15)
- SAVIENT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule orEDGAR Online(Wed, Apr 10)
- SAVIENT PHARMACEUTICALS INC Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- Savient Pharmaceuticals: Is Anything Left?at Seeking Alpha(Mon, Mar 25)
- Did These 5 Stocks Miss or Beat Analyst Expectations?at Wall St. Cheat Sheet(Sat, Mar 23)
- SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aEDGAR Online(Thu, Mar 21)
- New Star Analyst Rankings for Savient Pharmaceuticals IncStarMine(Wed, Mar 20)
- Savient Pharma falls on slower gout drug growthAP(Tue, Mar 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.20 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.23 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.31 |
|---|
| Mean Recommendation*: | 3.2 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy.
View More